Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.035
Filtrar
1.
Trop Doct ; 54(4): 369-371, 2024 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-39314191

RESUMO

Cutaneous larva migrans (CLM), commonly referred to as creeping eruption, is an infectious condition caused by various types of hookworms. It primarily affects the superficial layers of the skin owing to the absence of hyaluronidases and proteases. Typically, the distal lower extremities are the most commonly affected areas. The presence of distinctive lesions characterized by erythematous, winding, or serpentine tracks, slightly elevated from the skin surface, is indicative of the condition. Diagnosis primarily relies on clinical observation. Dermoscopy reveals multiple segmented yellowish-linear regions corresponding to pustules along the larval path. Treatment typically involves the use of topical and oral ivermectin, oral albendazole, and topical thiabendazole cream.


Assuntos
Larva Migrans , Larva Migrans/diagnóstico , Larva Migrans/tratamento farmacológico , Humanos , Albendazol/uso terapêutico , Albendazol/administração & dosagem , Eczema/tratamento farmacológico , Eczema/diagnóstico , Animais , Anti-Helmínticos/uso terapêutico , Anti-Helmínticos/administração & dosagem , Ivermectina/uso terapêutico , Ivermectina/administração & dosagem , Masculino , Doenças Negligenciadas/tratamento farmacológico , Doenças Negligenciadas/diagnóstico , Doenças Negligenciadas/parasitologia , Feminino , Tiabendazol/uso terapêutico , Tiabendazol/administração & dosagem , Pele/patologia , Pele/parasitologia , Dermoscopia
2.
Parasitol Res ; 121(9): 2623-2632, 2022 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-35779120

RESUMO

The spread of anthelmintic resistance (AR) in nematode populations threatens the viability of sheep production systems worldwide, and warrants the adoption of sensitive, practical, and standardized tests to detect AR. The aim of this study was to characterize the replacement of an Haemonchus contortus population resistant to benzimidazoles (BZDs) by a susceptible one, by means of both phenotypic and genotypic techniques. Phenotypic methods to assess BZD resistance included in vivo tests, such as the fecal egg count reduction test (FECRT), and in vitro tests, such as the egg hatch assay (EHA). Additionally, genotypification of polymorphisms associated with BZD resistance by sequencing a fragment of the isotype 1 ß-tubulin gene was carried out. The initial, BZD-resistant population (initial Balcarce population) exhibited an egg count reduction (ECR) of 59.3%. Following refugium replacement, the final population (final Balcarce population) exhibited an ECR of 95.2%. For the initial Balcarce population, the median effective dose (ED50) for the EHA was 0.607 µg thiabendazole (TBZ)/mL, with a rate of eclosion at a discriminating dose (EDD) of 0.1 µg TBZ/mL of 76.73%. For the final Balcarce population, ED50 was 0.02 µg TBZ/mL, and EDD was 1.97%. In the initial population, 93% of the analyzed individuals exhibited genotypic combinations associated with BZD resistance (53% Phe/Phe167-Tyr/Tyr200, 37% Phe/Tyr167-Phe/Tyr200, and 3% Phe/Tyr167-Glu/Leu198). Conversely, no combination associated with resistance was found in individuals from the final population. All of the tests were useful for detecting AR to BZDs. The results from the genetic and phenotypical studies were consistent, and the resulting information greatly aided in interpreting the outcomes of the population replacement and the potential impact of this strategy on management of AR.


Assuntos
Anti-Helmínticos , Hemoncose , Haemonchus , Doenças dos Ovinos , Animais , Anti-Helmínticos/farmacologia , Anti-Helmínticos/uso terapêutico , Benzimidazóis/farmacologia , Resistência a Medicamentos/genética , Hemoncose/tratamento farmacológico , Hemoncose/veterinária , Haemonchus/genética , Dinâmica Populacional , Ovinos , Doenças dos Ovinos/tratamento farmacológico , Doenças dos Ovinos/epidemiologia , Tiabendazol/farmacologia , Tiabendazol/uso terapêutico , Tubulina (Proteína)/genética
3.
J Pharmacol Exp Ther ; 380(1): 63-75, 2022 01.
Artigo em Inglês | MEDLINE | ID: mdl-34750208

RESUMO

Thiabendazole (TBZ), approved by the US Food and Drug Administration (FDA) for human oral use, elicits a potential anticancer activity on cancer cells in vitro and in animal models. Here, we evaluated the efficacy of TBZ in the treatment of human glioblastoma multiforme (GBM). TBZ reduced the viability of GBM cells (P3, U251, LN229, A172, and U118MG) relative to controls in a dose- and time-dependent manner. However, normal human astrocytes (NHA) exhibited a greater IC50 than tumor cell lines and were thus more resistant to its cytotoxic effects. 5-Ethynyl-2'-deoxyuridine (EdU)-positive cells and the number of colonies formed were decreased in TBZ-treated cells (at 150 µM, P < 0.05 and at 150 µM, P < 0.001, respectively). This decrease in proliferation was associated with a G2/M arrest as assessed with flow cytometry, and the downregulation of G2/M check point proteins. In addition, TBZ suppressed GBM cell invasion. Analysis of RNA sequencing data comparing TBZ-treated cells with controls yielded a group of differentially expressed genes, the functions of which were associated with the cell cycle and DNA replication. The most significantly downregulated gene in TBZ-treated cells was mini-chromosome maintenance protein 2 (MCM2). SiRNA knockdown of MCM2 inhibited proliferation, causing a G2/M arrest in GBM cell lines and suppressed invasion. Taken together, our results demonstrated that TBZ inhibited proliferation and invasion in GBM cells through targeting of MCM2. SIGNIFICANCE STATEMENT: TBZ inhibits the proliferation and invasion of glioblastoma cells by downregulating the expression of MCM2. These results support the repurposing of TBZ as a possible therapeutic drug in the treatment of GBM.


Assuntos
Anti-Helmínticos/uso terapêutico , Antineoplásicos/farmacologia , Neoplasias Encefálicas/tratamento farmacológico , Proliferação de Células/efeitos dos fármacos , Glioblastoma/tratamento farmacológico , Componente 2 do Complexo de Manutenção de Minicromossomo/metabolismo , Tiabendazol/farmacologia , Animais , Anti-Helmínticos/farmacologia , Antineoplásicos/uso terapêutico , Neoplasias Encefálicas/metabolismo , Linhagem Celular , Linhagem Celular Tumoral , Movimento Celular/efeitos dos fármacos , Células Cultivadas , Reposicionamento de Medicamentos , Glioblastoma/metabolismo , Humanos , Camundongos , Camundongos Nus , Tiabendazol/uso terapêutico
4.
Trop Med Int Health ; 26(11): 1419-1426, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-34370367

RESUMO

OBJECTIVES: Human toxocariasis is a widespread zoonosis for which a chemotherapy decision and therapy effectiveness are difficult to determine. We aimed to investigate the kinetic profile of clinical and laboratory findings and treatment outcome of patients with toxocariasis in Vietnam. METHODS: The prospective study was conducted between October 2017 and June 2019. The diagnosis of toxocariasis was established based on clinical, laboratory (eosinophilia, raised IgE concentration) and serological (positive Toxocara IgG ELISA) evaluation as well as the exclusion of another helminthic co-infection. The patients were followed up after seven days, then one, three and six months after chemotherapy by thiabendazole. RESULTS: The study involved 80 patients with a mean age of 41.6 ± 15.2 years of whom 58.8% were female. At three and six months after chemotherapy, most patients demonstrated resolution of clinical signs and symptoms, eosinophil count and IgE concentration but not in the proportion of IgG seropositivity. Skin lesions and eosinophilia resolved earlier than the other symptoms (one month after treatment). About four-fifths of the patients were "cured" after three and six months of follow-up; 33.8% showed side effects to thiabendazole therapy but no severe events were reported. The most common adverse reaction was neurologic symptoms followed by gastrointestinal or skin manifestations which lasted as long as 4 days. CONCLUSIONS: In toxocariasis patients, cutaneous manifestations and eosinophilia resolve more rapidly than other clinical and laboratory findings while IgG titre has a very slow kinetic after therapy. Thiabendazole seems to be a potential alternative for the treatment of human toxocariasis.


Assuntos
Toxocaríase/diagnóstico , Adolescente , Adulto , Idoso , Animais , Anti-Helmínticos/administração & dosagem , Anti-Helmínticos/uso terapêutico , Anticorpos Anti-Helmínticos/sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Tiabendazol/administração & dosagem , Tiabendazol/uso terapêutico , Toxocara/imunologia , Toxocaríase/sangue , Toxocaríase/tratamento farmacológico , Toxocaríase/epidemiologia , Vietnã/epidemiologia , Adulto Jovem , Zoonoses/diagnóstico , Zoonoses/tratamento farmacológico
5.
Int J Infect Dis ; 105: 739-742, 2021 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-33737138

RESUMO

Guinea worm (GW) disease, caused by Dracunculus medinensis, is an almost eradicated waterborne zoonotic disease. The World Health Organization (WHO) currently lists GW as endemic in only five African countries. In July 2020, the Vietnamese public health surveillance system detected a hanging worm in a 23-year-old male patient, who did not report any travel to Africa or any country previously endemic for GW. The patient was hospitalized with symptoms of fatigue, anorexia, muscle aches, and abscesses, with worms hanging out of the skin in the lower limbs. The worms were retrieved from the lesions and microscopically examined in Vietnam, identifying structures compatible with Dracunculus spp. and L1-type larvae. A section of this parasite was sent to the Centers for Disease Control and Prevention (CDC) in Atlanta, United States, for confirmatory diagnosis of GW. The adult worm had cuticle structures compatible with Dracunculus parasites, although the length of L1 larvae was about 339 µm, substantially shorter than D. medinensis. DNA sequence analysis of the 18S small subunit rRNA gene confirmed that this parasite was not GW, and determined that the sample belonged to a Dracunculus sp. not previously reported in GenBank that clustered with the animal-infective Dracunculus insignis and Dracunculus lutrae, located in a different clade than D. medinensis. This study highlights the importance of effective public health surveillance systems and the collaborative work of local public health authorities from Vietnam with the WHO and CDC in efforts to achieve the eradication of GW.


Assuntos
Dracunculíase/diagnóstico , Dracunculus/classificação , Dracunculus/genética , Animais , Anti-Helmínticos/uso terapêutico , Dracunculíase/tratamento farmacológico , Dracunculíase/parasitologia , Dracunculus/isolamento & purificação , Humanos , Larva/classificação , Larva/genética , Masculino , Vigilância em Saúde Pública , Tiabendazol/uso terapêutico , Resultado do Tratamento , Vietnã , Doenças Transmitidas pela Água/diagnóstico , Adulto Jovem
8.
Emerg Infect Dis ; 26(3): 401-408, 2020 03.
Artigo em Inglês | MEDLINE | ID: mdl-32091375

RESUMO

Clinical characteristics of disseminated strongyloidiasis, the severest form of strongyloidiasis, are not well described. We conducted a retrospective, consecutive chart review of patients with disseminated strongyloidiasis admitted to Okinawa Chubu Hospital in Okinawa, Japan, during January 1975-December 2017. The 70 patients were classified into 3 clinical phenotypes: dissemination (32 patients [45.7%]), occult dissemination with meningitis caused by enteric organisms (12 patients [17.1%]), and occult dissemination with culture-negative suppurative meningitis (26 patients [37.1%]). Associated mortality rates were 56.3%, 16.7%, and 11.5%, respectively, and sepsis occurred in 40.6%, 58.3%, and 11.5% of cases, respectively. Common symptoms included fever (52.9% of patients), headache (32.9%), and altered mental status (24.3%). Patients were treated with thiabendazole (before 2003) or ivermectin (after 2003). Our findings show that disseminated strongyloidiasis has clinical phenotypes in terms of severity and that identification of occult dissemination, a mild form with prominent neurologic manifestations, is lifesaving.


Assuntos
Meningites Bacterianas/epidemiologia , Estrongiloidíase/epidemiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Anti-Helmínticos/uso terapêutico , Feminino , Humanos , Ivermectina/uso terapêutico , Japão/epidemiologia , Masculino , Prontuários Médicos , Meningites Bacterianas/tratamento farmacológico , Meningites Bacterianas/etiologia , Pessoa de Meia-Idade , Estudos Retrospectivos , Estrongiloidíase/tratamento farmacológico , Estrongiloidíase/etiologia , Tiabendazol/uso terapêutico , Adulto Jovem
10.
Rev Soc Bras Med Trop ; 52: e20180229, 2019 Jul 18.
Artigo em Inglês | MEDLINE | ID: mdl-31340353

RESUMO

Sarcoidosis is a rare multisystem chronic inflammatory disease in children. We present a case of a five-year-old child with clinical features mimicking several diseases, including tuberculosis. After failure of treatment based on the suspected diagnosis, an axillary lymph node biopsy showed noncaseating granulomas compatible with sarcoidosis and appropriate treatment was then started.


Assuntos
Sarcoidose/diagnóstico , Anti-Helmínticos/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Biópsia , Brasil , Pré-Escolar , Diagnóstico Diferencial , Feminino , Humanos , Linfoma/diagnóstico , Prednisolona/uso terapêutico , Sarcoidose/tratamento farmacológico , Tiabendazol/uso terapêutico , Tomografia Computadorizada por Raios X , Tuberculose/diagnóstico
11.
Rev. Soc. Bras. Med. Trop ; Rev. Soc. Bras. Med. Trop;52: e20180229, 2019. graf
Artigo em Inglês | LILACS | ID: biblio-1013304

RESUMO

Abstract Sarcoidosis is a rare multisystem chronic inflammatory disease in children. We present a case of a five-year-old child with clinical features mimicking several diseases, including tuberculosis. After failure of treatment based on the suspected diagnosis, an axillary lymph node biopsy showed noncaseating granulomas compatible with sarcoidosis and appropriate treatment was then started.


Assuntos
Humanos , Feminino , Pré-Escolar , Sarcoidose/diagnóstico , Sarcoidose/tratamento farmacológico , Tiabendazol/uso terapêutico , Tuberculose/diagnóstico , Biópsia , Brasil , Prednisolona/uso terapêutico , Tomografia Computadorizada por Raios X , Diagnóstico Diferencial , Linfoma/diagnóstico , Anti-Helmínticos/uso terapêutico , Anti-Inflamatórios/uso terapêutico
12.
Rev Chilena Infectol ; 34(1): 47-53, 2017 Feb.
Artigo em Espanhol | MEDLINE | ID: mdl-28394981

RESUMO

The strongyloidiasis is a parasitic disease that poses as a serious public health problem, mainly in tropical and subtropical countries. Over the years, some conditions, such as advances in corticosteroid treatment and immunosuppressive diseases, have improved not only the increase in cases of strongyloidiasis, but also the emergence of severe forms of the disease and / or deaths. For these reasons, the objective of this study is to make a critical analysis of the occurrence of strongyloidiasis in patients with comorbidities, describing clinical and epidemiological characteristics associated with these diseases that can highlight the importance of monitoring this parasitosis in most susceptible groups.


Assuntos
Estrongiloidíase/epidemiologia , Alcoolismo/epidemiologia , Animais , Antiparasitários/uso terapêutico , Comorbidade , Diabetes Mellitus/epidemiologia , Feminino , Infecções por HIV/epidemiologia , Infecções por HTLV-I/epidemiologia , Humanos , Ivermectina/uso terapêutico , Masculino , Pessoa de Meia-Idade , Transplante de Órgãos/efeitos adversos , Fatores de Risco , Neoplasias Gástricas/epidemiologia , Estrongiloidíase/tratamento farmacológico , Tiabendazol/uso terapêutico
13.
Rev. chil. infectol ; Rev. chil. infectol;34(1): 47-53, feb. 2017.
Artigo em Espanhol | LILACS | ID: biblio-844444

RESUMO

The strongyloidiasis is a parasitic disease that poses as a serious public health problem, mainly in tropical and subtropical countries. Over the years, some conditions, such as advances in corticosteroid treatment and immunosuppressive diseases, have improved not only the increase in cases of strongyloidiasis, but also the emergence of severe forms of the disease and / or deaths. For these reasons, the objective of this study is to make a critical analysis of the occurrence of strongyloidiasis in patients with comorbidities, describing clinical and epidemiological characteristics associated with these diseases that can highlight the importance of monitoring this parasitosis in most susceptible groups.


La estrongiloidiasis es una parasitosis que representa un grave problema de salud pública, principalmente en países ubicados en regiones tropicales y subtropicales. A lo largo de los años, algunas condiciones, como por ejemplo, avances en el tratamiento con corticosteroides y enfermedades que evolucionan con inmunosupresión, han favorecido no solamente al aumento de casos de estrongiloidiasis, sino también al surgimiento de formas graves de la enfermedad y/u decesos. Por lo expuesto, el objetivo del presente estudio fue realizar un análisis crítico de la ocurrencia de la estrongiloidiasis en portadores de co-morbilidades, describiendo las características clínico-epidemiológicas de esa asociación que puedan resaltar la importancia de vigilar esta parasitosis en grupos considerados más susceptibles.


Assuntos
Humanos , Animais , Masculino , Feminino , Pessoa de Meia-Idade , Estrongiloidíase/epidemiologia , Neoplasias Gástricas/epidemiologia , Estrongiloidíase/tratamento farmacológico , Tiabendazol/uso terapêutico , Ivermectina/uso terapêutico , Infecções por HTLV-I/epidemiologia , Comorbidade , Infecções por HIV/epidemiologia , Fatores de Risco , Transplante de Órgãos/efeitos adversos , Diabetes Mellitus/epidemiologia , Alcoolismo/epidemiologia , Antiparasitários/uso terapêutico
14.
Ann Parasitol ; 63(4): 317-322, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-29419992

RESUMO

Fecal egg count reduction (FECR) test with albendazole and egg hatch test (EHT) with thiabendazole (TBZ) were performed in a dairy goat herd suspected of anthelmintic resistance to benzimidazoles. The herd had been regularly dewormed with fenbendazole for 5 previous years and despite that it remained infected with several species of gastrointestinal nematodes (Trichostrongylus colubriformis, Teladorsagia circumcincta, and Haemonchus contortus). Albendazole was administered per os at dose of 20 mg/kg to 10 goats (treated group), while 10 other goats remained untreated (control group). Fecal egg count (FEC) was determined using McMaster egg counting method before and 7 days after the treatment in the treated group, and once (at the latter moment) in the control group. EHT was performed on the pooled rectal sample collected from treated goats. EHT comprised the negative control and 7 consecutive concentrations of TBZ (0.05, 0.1, 0.2, 0.3, 0.5, 1.0, 2.0 µg/ml) according to the standard procedure. Two hundred eggs/larvae were counted to determine percentage of unhatched eggs, which was adjusted by the natural mortality. TBZ dose effective in preventing hatching of 50% of eggs (ED50) was determined using the log-probit transformation. Median FEC (range) before the treatment was 1000 (250­3450) epg in the treated group and dropped to 150 (50­500) epg after the treatment (p=0.005). Median FEC (range) after the treatment was also significantly lower in the treated than in control group (p=0.009), where it was 725 (0­5050) epg. FECR between the treated and control group was 81% (95% CI: 49%, 93%). FECR in the treated group was 83% and 74% based on average and individual approach, respectively. ED50 value of TBZ was 0.78 µg/ml. Only H. contortus persisted in the treated group after treatment. The results indicate resistance of H. contortus to a benzimidazole anthelmintic, which is the first such case reported in Polish goats.


Assuntos
Resistência a Medicamentos , Gastroenteropatias/veterinária , Doenças das Cabras/parasitologia , Hemoncose/veterinária , Haemonchus/efeitos dos fármacos , Tiabendazol/farmacologia , Animais , Anti-Helmínticos/administração & dosagem , Anti-Helmínticos/farmacologia , Anti-Helmínticos/uso terapêutico , Relação Dose-Resposta a Droga , Fezes , Gastroenteropatias/epidemiologia , Gastroenteropatias/parasitologia , Doenças das Cabras/epidemiologia , Cabras , Hemoncose/epidemiologia , Hemoncose/parasitologia , Contagem de Ovos de Parasitas/veterinária , Polônia/epidemiologia , Tiabendazol/administração & dosagem , Tiabendazol/uso terapêutico
16.
Cochrane Database Syst Rev ; (1): CD007745, 2016 Jan 18.
Artigo em Inglês | MEDLINE | ID: mdl-26778150

RESUMO

BACKGROUND: Strongyloidiasis is a gut infection with Strongyloides stercoralis which is common world wide. Chronic infection usually causes a skin rash, vomiting, diarrhoea or constipation, and respiratory problems, and it can be fatal in people with immune deficiency. It may be treated with ivermectin or albendazole or thiabendazole. OBJECTIVES: To assess the effects of ivermectin versus benzimidazoles (albendazole and thiabendazole) for treating chronic strongyloides infection. SEARCH METHODS: We searched the Cochrane Infectious Diseases Group Specialized Register (24 August 2015); the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library; MEDLINE (January 1966 to August 2015); EMBASE (January 1980 to August 2015); LILACS (August 2015); and reference lists of articles. We also searched the metaRegister of Controlled Trials (mRCT) using 'strongyloid*' as a search term, reference lists, and conference abstracts. SELECTION CRITERIA: Randomized controlled trials of ivermectin versus albendazole or thiabendazole for treating chronic strongyloides infection. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data and assessed risk of bias in the included trials. We used risk ratios (RRs) with 95% confidence intervals (CIs) and fixed- or random-effects models. We pooled adverse event data if the trials were sufficiently similar in their adverse event definitions. MAIN RESULTS: We included seven trials, enrolling 1147 participants, conducted between 1994 and 2011 in different locations (Africa, Southeast Asia, America and Europe).In trials comparing ivermectin with albendazole, parasitological cure was higher with ivermectin (RR 1.79, 95% CI 1.55 to 2.08; 478 participants, four trials, moderate quality evidence). There were no statistically significant differences in adverse events (RR 0.80, 95% CI 0.59 to 1.09; 518 participants, four trials, low quality evidence).In trials comparing ivermectin with thiabendazole, there was little or no difference in parasitological cure (RR 1.07, 95% CI 0.96 to 1.20; 467 participants, three trials, low quality evidence). However, adverse events were less common with ivermectin (RR 0.31, 95% CI 0.20 to 0.50; 507 participants; three trials, moderate quality evidence).In trials comparing different dosages of ivermectin, taking a second dose of 200 µg/kg of ivermectin was not associated with higher cure in a small subgroup of participants (RR 1.02, 95% CI 0.94 to 1.11; 94 participants, two trials).Dizziness, nausea, and disorientation were commonly reported in all drug groups. There were no reports of serious adverse events or death. AUTHORS' CONCLUSIONS: Ivermectin results in more people cured than albendazole, and is at least as well tolerated. In trials of ivermectin with thiabendazole, parasitological cure is similar but there are more adverse events with thiabendazole.


Assuntos
Albendazol/uso terapêutico , Anti-Helmínticos/uso terapêutico , Ivermectina/uso terapêutico , Strongyloides stercoralis , Estrongiloidíase/tratamento farmacológico , Tiabendazol/uso terapêutico , Albendazol/efeitos adversos , Animais , Anti-Helmínticos/efeitos adversos , Humanos , Ivermectina/efeitos adversos , Ensaios Clínicos Controlados Aleatórios como Assunto , Tiabendazol/efeitos adversos
19.
Am J Trop Med Hyg ; 92(3): 601-4, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25548379

RESUMO

Although meningitis secondary to chronic strongyloidiasis is a rare complication, it is associated with a high mortality rate. Recurrent meningitis can occur if the underlying parasitic infection is left untreated. We report five cases of recurrent meningitis related to chronic strongyloidiasis that were associated with human T-lymphotropic virus type 1 (HTLV-1) infection. Common causative organisms are Escherichia coli, Streptococcus bovis, and Klebsiella pneumonia. One patient died during the second episode of meningitis. Three patients showed significant gastrointestinal and respiratory symptoms before developing headache and fever. In four cases, patients developed multiple recurrences even with the treatment of thiabendazol. Ivermectin seems to be a better agent compared with thiabendazol to achieve eradication of strongyloidiasis.


Assuntos
Ivermectina/uso terapêutico , Meningites Bacterianas/etiologia , Estrongiloidíase/complicações , Estrongiloidíase/tratamento farmacológico , Tiabendazol/uso terapêutico , Adulto , Idoso , Anti-Helmínticos/administração & dosagem , Anti-Helmínticos/uso terapêutico , Doença Crônica , Feminino , Infecções por HTLV-I/complicações , Vírus Linfotrópico T Tipo 1 Humano , Humanos , Ivermectina/administração & dosagem , Masculino , Meningites Bacterianas/patologia , Pessoa de Meia-Idade , Estudos Retrospectivos , Tiabendazol/administração & dosagem , Adulto Jovem
20.
Int Health ; 6(4): 273-81, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-25173343

RESUMO

Strongyloides stercoralis is one of the common parasites in tropical areas. It can result in severe clinical syndromes, hyperinfection syndrome or disseminated strongyloidiasis in immunocompromised patients. The treatment of strongyloidiasis is a challenge for clinicians in clinical practice. Failure of treatment is due to autoinfection caused by the parasite life cycle and impairment of host immunity. Ivermectin currently is the treatment of choice. When compared with thiabendazole, it has shown a similar efficacy with better tolerability. However, there is neither consensus in duration of treatment nor in repetition of doses. The keys for management of this tough parasite include proper evaluation and prevention. Stool examination with high sensitivity techniques such as Baermann technique, filter-paper culture and agar-plate culture and specific IgG serology should be used in evaluation for 1 to 2 years. Screening, both stool examination and serology, before patients have immunosuppressive treatment is needed to prevent the severe form of strongyloidiasis.


Assuntos
Antiparasitários/uso terapêutico , Strongyloides stercoralis , Estrongiloidíase/tratamento farmacológico , Animais , Anti-Helmínticos/uso terapêutico , Doença Crônica , Gerenciamento Clínico , Humanos , Ivermectina/uso terapêutico , Estrongiloidíase/prevenção & controle , Tiabendazol/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA